Physician profile
Marc Tarle
NPI 1992834683
$24,412.10
in general payments reported to CMS, 2019-2025
39 companies · $4,914 in 2025
The $4,914 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,355 · 2020: $2,313 · 2021: $3,102 · 2022: $3,725 · 2023: $3,848 · 2024: $4,154 · 2025: $4,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,809.48 |
| Education | $106.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,821.15 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $2,556.70 | 2019-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $2,451.21 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $1,917.44 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,772.47 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $1,415.61 | 2019-2025 | Abilify Maintena, Rexulti |
| Alkermes, INC. | $1,336.26 | 2019-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $1,215.82 | 2022-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,153.16 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $949.07 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $758.12 | 2019-2025 | Fanapt, Hetlioz |
| Neuronetics, INC. | $661.71 | 2019-2025 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $640.34 | 2020-2025 | Trintellix |
| Corium, LLC | $609.50 | 2022-2024 | Azstarys |
| Eisai INC. | $524.05 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Tarle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.